186 related articles for article (PubMed ID: 36778868)
1. Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease.
Ying X; Rongjiong Z; Kahaer M; Chunhui J; Wulasihan M
Front Microbiol; 2023; 14():1088187. PubMed ID: 36778868
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
Tian F; Zheng Z; Zhang D; He S; Shen J
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
[TBL] [Abstract][Full Text] [Related]
3. Clinical Efficacy and Safety of Liraglutide and Dapagliflozin on Glucose and Lipid Metabolism and Insulin Function in Patients with Type 2 Diabetes Mellitus.
Ma J; Fu J; Guo N; Liu Z
Altern Ther Health Med; 2024 Jan; ():. PubMed ID: 38294744
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice.
Liu Q; Cai BY; Zhu LX; Xin X; Wang X; An ZM; Li S; Hu YY; Feng Q
Life Sci; 2020 Nov; 261():118457. PubMed ID: 32961235
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats.
Xu X; Wang W; Lin L; Chen P
Tissue Cell; 2020 Oct; 66():101382. PubMed ID: 32933722
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects.
Wang Z; Saha S; Van Horn S; Thomas E; Traini C; Sathe G; Rajpal DK; Brown JR
Endocrinol Diabetes Metab; 2018 Jan; 1(1):e00009. PubMed ID: 30815546
[TBL] [Abstract][Full Text] [Related]
8. [Effect of metformin on the expression of SIRT1 and UCP2 in rat liver of type 2 diabetes mellitus and nonalcoholic fatty liver].
Xu J; Li N; Wang J; Zhang C; Ding S; Jiao Y; Zhang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):882-7. PubMed ID: 24071688
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
[TBL] [Abstract][Full Text] [Related]
10. Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease.
Lin X; Zhang Z; Chen JM; Xu YY; Ye HR; Cui J; Fang Y; Jin Y; Zhu DR; Yuan L
Genet Mol Res; 2015 Apr; 14(2):2940-6. PubMed ID: 25966055
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
Feng W; Gao C; Bi Y; Wu M; Li P; Shen S; Chen W; Yin T; Zhu D
J Diabetes; 2017 Aug; 9(8):800-809. PubMed ID: 28332301
[TBL] [Abstract][Full Text] [Related]
12. [Zuogui Jiangtang Qinggan Prescription promotes recovery of intestinal mucosal barrier in mice with type 2 diabetes mellitus and nonalcoholic fatty liver disease by improving intestinal flora homeostasis].
Zou JJ; Li H; Zhou M; Huang QQ; Wu YJ; Yu R
Zhongguo Zhong Yao Za Zhi; 2023 Jan; 48(2):525-533. PubMed ID: 36725242
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.
Liu Y; Jiang X; Chen X
Lipids Health Dis; 2017 Dec; 16(1):227. PubMed ID: 29197387
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
15. [Study of the effect of liraglutide on the correlation between NLRP3 inflammasome and non-alcoholic fatty liver disease].
Ma ZZ; Ao N; Yang N; Yang J; Jin S; Du C; Du J
Zhonghua Gan Zang Bing Za Zhi; 2022 Jun; 30(6):624-630. PubMed ID: 36038324
[No Abstract] [Full Text] [Related]
16. Correlation of CD3+/CD4+, and serum CK-18 fragment levels with glucose and lipid metabolism in elderly type 2 diabetes patients with nonalcoholic fatty liver disease.
Zhao C; Lou F; Li X; Ma J; Zhu Z; Li H; Zhai Y; Chen H; Zhang Q; Liu Z; Xiao S
Am J Transl Res; 2021; 13(4):2546-2554. PubMed ID: 34017413
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of metformin combined with liraglutide on the glucose and lipid metabolism, vascular endothelial function, and oxidative stress of patients with T2DM and metabolic syndrome.
Liu Z
Pak J Med Sci; 2024; 40(1Part-I):26-30. PubMed ID: 38196473
[TBL] [Abstract][Full Text] [Related]
18. The effect of metformin combined with liraglutide on gut microbiota of Chinese patients with type 2 diabetes.
Niu X; Lu P; Huang L; Sun Y; Jin M; Liu J; Li X
Int Microbiol; 2024 Feb; 27(1):265-276. PubMed ID: 37316616
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
Smits MM; Fluitman KS; Herrema H; Davids M; Kramer MHH; Groen AK; Belzer C; de Vos WM; Cahen DL; Nieuwdorp M; van Raalte DH
Diabetes Metab; 2021 Sep; 47(5):101223. PubMed ID: 33429063
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice.
Moreira GV; Azevedo FF; Ribeiro LM; Santos A; Guadagnini D; Gama P; Liberti EA; Saad M; Carvalho C
J Nutr Biochem; 2018 Dec; 62():143-154. PubMed ID: 30292107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
